Important note: Information in this article was accurate in 2005. The state of the art may have changed since the publication date.
PRNewswire - November 30, 2005
* HIV positive patients taking COMBIVIR achieved a >/= 95 percent adherence rate more than twice as often as patients taking lamivudine and zidovudine separately.
* Mean adherence was higher for patients taking COMBIVIR (85 percent) compared to patients taking the separate components, lamivudine and zidovudine, (75 percent) when considering the population subgroup (1997-2000) (p<0.001).
RESEARCH TRIANGLE PARK, N.C., Nov. 30 /PRNewswire/ -- Fixed-dose combination therapies for HIV may increase the likelihood of treatment adherence among patients, according to a recently published study of 2,112 patients conducted by GlaxoSmithKline. Patients taking a fixed-dose combination of lamivudine (3TC) 150 mg and zidovudine (ZDV) 300 mg (COMBIVIR(R)) achieved >/= 95 percent adherence more than twice as often as patients whose regimens included 3TC and ZDV as separate pills. The results were published in the November issue of AIDS Care.
"Pill burden is an important factor in achieving desirable adherence rates. Fixed-dose combination products have been available for almost a decade, with COMBIVIR being the first to market. However, until now, limited data have existed demonstrating the ability of these products to facilitate adherence. That's why we are encouraged by the results of this study," said Mark Shaefer, Pharm. D., acting vice president, HIV, Infectious Disease Medicine Development Center at GSK.
The retrospective, longitudinal cohort study analyzed 60-day prescription refill Medicaid claims data from 1995-2001. The data combined to cover more than 3.3 million patient lives.
To adjust for the time prior to the approval of a fixed-dose combination therapy (COMBIVIR) in 1997, two sets of adjusted analysis were conducted, one for the total population (n=2,112) over the entire study period (1995-2001) and another for the population subgroup (n=1,427) that received separate pills or combination therapy from September 1997 to December 2000. The investigators focused on the results for the subgroup analysis to minimize the potential influence of other time-related variables on the outcome.
The primary study outcome was medication adherence as assessed by prescription refill data. The adherence ratio was calculated for each prescription during the follow up period; for example, a patient with a prescription claim for a 30-day supply who did not refill the prescription until 45 days later would be considered 67 percent adherent (30/45 = 67 percent). The threshold for adherence was set at 95 percent; existing evidence suggests that this level of adherence is associated with a lower risk of virologic failure. A patient would have been considered non-adherent on or after the 32nd day following a 30-day prescription refill.
Mean adherence was higher for patients taking COMBIVIR (85 percent) compared to patients taking the separate components, lamivudine and zidovudine, (75 percent) when considering the population subgroup (p<0.001). Similarly, in measuring adherence rates for the subpopulation, patients taking COMBIVIR achieved >/= 95 percent adherence more than twice as often as patients who took the separate components (36 percent vs. 16 percent respectively).*
Researchers also reported that findings from analyses conducted with the entire population during the complete study period (1995-2001) were similar to those found in the subgroup analysis.
"Fixed-dose combinations like COMBIVIR can reduce treatment complexity when compared to their separate components. Treatment complexity is a common barrier to adherence and fixed-dose combination products should be considered for patients with difficulty adhering to their medication regimen," said Shaefer.
COMBIVIR was the first two-drug combination tablet approved for HIV treatment and is one of the most studied and widely prescribed dual nucleoside combination products. One out of five people currently taking antiretrovirals in the United States is prescribed COMBIVIR.
About COMBIVIR
HIV medicines do not cure HIV infection/AIDS or prevent passing HIV to others. COMBIVIR is a combination tablet containing Epivir(R) (lamivudine, 3TC) and Retrovir(R) (zidovudine, AZT). COMBIVIR is indicated in combination with other antiretroviral agents for the treatment of HIV infection. Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported. Zidovudine has been associated with hematologic toxicity including neutropenia and severe anemia, especially in advanced HIV disease, and with symptomatic myopathy after prolonged use. Severe acute exacerbations of hepatitis B have been reported in patients who are co-infected with hepatitis B virus (HBV) and HIV and have discontinued lamivudine, which is one component of COMBIVIR. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who discontinue COMBIVIR and are co-infected with HIV and HBV. If appropriate, initiation of antihepatitis B therapy may be warranted. Redistribution/accumulation of body fat has been observed in patients receiving antiretroviral therapy. The causal relationship, mechanism, and long-term consequences of these events are currently unknown. The most frequent adverse events are headache (35%), nausea (33%), malaise/fatigue (27%), and nasal signs and symptoms (20%). For complete prescribing information about COMBIVIR, visit http://us.gsk.com/products/assets/us_combivir.pdf.
GlaxoSmithKline
GlaxoSmithKline is one of the world's leading research-based pharmaceutical and healthcare companies and an industry leader in HIV research and therapies. The company is engaged in basic research programs designed to investigate new targets to treat HIV.
GSK's Bridges to Access program can help provide qualified individuals with access to GSK's antiretroviral medications, as well as help identify insurance or other support for medications. Patients may be eligible for this program if they are not eligible for prescription drug benefits through any other private or public insurer, payer or program. In 2004, GlaxoSmithKline donated more than $372.5 million worth of prescription drugs to 475,000 patients. For more information, visit http://www.bridgestoaccess.gsk.com or call 1-866-PATIENT.
* Data provided by GlaxoSmithKline.
Media contact:
Mary Faye Dark, GlaxoSmithKline -- 919/483-2839
SOURCE GlaxoSmithKline
Contact: Mary Faye Dark of GlaxoSmithKline, +1-919-483-2839
051130
PR051156
Copyright © 2005 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.prnewswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .